Shares of EXACT Sciences Co. (NASDAQ:EXAS) have earned an average recommendation of “Buy” from the fifteen research firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $109.40.

Several research firms have recently weighed in on EXAS. Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 30th. BidaskClub cut shares of EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. Canaccord Genuity raised their price objective on shares of EXACT Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, UBS Group lifted their target price on shares of EXACT Sciences from $115.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st.

NASDAQ:EXAS traded down $2.26 during trading hours on Tuesday, hitting $111.51. The stock had a trading volume of 45,589 shares, compared to its average volume of 1,667,387. The business’s 50 day moving average price is $103.24. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13. EXACT Sciences has a one year low of $47.78 and a one year high of $117.98. The stock has a market cap of $14.61 billion, a price-to-earnings ratio of -81.79 and a beta of 1.68.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.01). EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The firm had revenue of $162.00 million during the quarter, compared to the consensus estimate of $153.07 million. During the same period in the previous year, the business earned ($0.33) earnings per share. The firm’s revenue for the quarter was up 79.4% on a year-over-year basis. Research analysts predict that EXACT Sciences will post -2.21 EPS for the current year.

In related news, insider Mark Stenhouse sold 11,192 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total value of $1,035,707.68. Following the completion of the transaction, the insider now directly owns 25,500 shares of the company’s stock, valued at approximately $2,359,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of EXAS. First Hawaiian Bank grew its stake in EXACT Sciences by 160.0% in the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 200 shares during the period. Buffington Mohr McNeal acquired a new position in shares of EXACT Sciences during the 1st quarter valued at about $30,000. Mosaic Family Wealth LLC acquired a new position in shares of EXACT Sciences during the 1st quarter valued at about $37,000. Karp Capital Management Corp purchased a new stake in EXACT Sciences in the 4th quarter valued at about $38,000. Finally, Shine Investment Advisory Services Inc. raised its holdings in EXACT Sciences by 130.2% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after buying an additional 250 shares during the period. 86.27% of the stock is owned by hedge funds and other institutional investors.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: What is a Real Estate Investment Trust (REIT)?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.